{"id":"W1814699096","doi":"10.1016/j.ctrv.2004.08.002","title":"Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.","year":2004,"lang":"en","type":"letter","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Gefitinib; Medicine; Carboplatin; Paclitaxel; Lung cancer; Chemotherapy; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005482406,0.002399033,0.005096148,0.0007073262,0.0002161865,0.0002321655,0.0003141035,0.0008183024,0.0002068429],"category_scores_gemma":[0.00003022522,0.00159857,0.0003004381,0.0009604993,0.0002409414,0.0006861713,0.00007457774,0.00211704,0.000001978097],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006388156,"about_ca_system_score_gemma":0.004141427,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.08312356,"about_ca_topic_score_gemma":0.1598435,"domain_scores_codex":[0.9920209,0.0004654111,0.002375298,0.002831019,0.000821693,0.001485663],"domain_scores_gemma":[0.9950166,0.0005798415,0.002388271,0.001196044,0.0003452953,0.0004738976],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2660007,0.02234966,0.4287684,0.01669342,0.008818368,0.004553122,0.04191408,0.002387171,0.0076031,0.00001550605,0.01103746,0.189859],"study_design_scores_gemma":[0.8783428,0.01689292,0.02626301,0.02598039,0.005993706,0.00002574494,0.001369648,0.0009150907,0.00266406,0.00001785244,0.03764297,0.003891816],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8928692,0.04255258,0.00006519874,0.03167735,0.0007036021,0.02897067,0.002573028,0.0001004572,0.000487968],"genre_scores_gemma":[0.5401073,0.2716936,0.009373163,0.06727476,0.001954939,0.08897269,0.01299256,0.001474981,0.006156041],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6123421,"threshold_uncertainty_score":0.9988747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01463295194877606,"score_gpt":0.3232133757697233,"score_spread":0.3085804238209472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}